ATTENEX
Attenex Corp. is changing the way corporations manage e-discovery. With an open software platform and industry expertise, Attenex enables corporations and their law firms to establish standardized e-discovery processes that reduce the risk, complexity and cost of litigation, regulatory requests and internal investigations. Whether deployed on-premise or as a hosted service through the industry's largest network of global service providers, Attenex Patterns software provides corporations with control of e-discovery and the flexibility to choose the best solution for their needs.
ATTENEX
Industry:
Advice Legal Software
Founded:
2000-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.attenex.com
Total Employee:
5001+
Status:
Closed
Contact:
206-373-6500
Total Funding:
5 M USD
Technology used in webpage:
Amazon Route 53 Mimecast
Similar Organizations
Borderwise
Borderwise is an online interface for preparing complete immigration applications based on answers to simple questions.
Venio Systems
VenioOne, a unified eDiscovery platform, is designed to provide law firms, corporations and government entities.
Investors List
Voyager Capital
Voyager Capital investment in Series B - Attenex
Official Site Inspections
http://www.attenex.com
- Host name: 216.87.148.114
- IP address: 216.87.148.114
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Attenex"
Athenex Company Profile 2024: Valuation, Funding & Investors
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is …See details»
Athenex - LinkedIn
Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies.See details»
Athenex - Crunchbase Company Profile & Funding
Organization. Athenex . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Athenex focuses on the development and …See details»
Athenex - Crunchbase Company Profile & Funding
Organization. Athenex . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... Athenex offers pharmacists' products including ampicillin for …See details»
Athenex Inc - Company Profile and News - Bloomberg Markets
Company profile page for Athenex Inc including stock price, company news, executives, board members, and contact informationSee details»
Athenex, Inc. - AnnualReports.com
Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current … More clinical pipeline is derived from four different …See details»
Athenex Company Profile - Office Locations, Competitors ... - Craft
Athenex has 1 employees across 11 locations and $102.82 m in annual revenue in FY 2022. See insights on Athenex including office locations, competitors, revenue, financials, executives, …See details»
Athenex - Funding, Financials, Valuation & Investors - Crunchbase
Athenex is registered under the ticker NASDAQ:ATNX . Their stock opened with $11.00 in its Jun 14, 2017 IPO. Athenex is funded by 4 investors. Kingdon Capital and OrbiMed are the most …See details»
Athenex's bankruptcy won't be the end of drug development in …
Jun 1, 2023 Athenex’s Oraxol made it past the highest risks. Phase I of clinical trials is really the first trial on humans, Dunbar said, while Phase II further explores testing for the right dosing, …See details»
Athenex Announces Appointment of Chief Financial Officer
Feb 22, 2022 Mr. Annoni, Chief Financial Officer, said, “I am honored to join Athenex’s leadership team at such a pivotal time and to lead its finance organization as we refocus the …See details»
Athenex, Inc. Reaches Agreement With Lenders to …
May 14, 2023 To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process ...See details»
ImmunityBio Completes Acquisition of Athenex’s Interest in …
Feb 15, 2022 This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding ImmunityBio’s …See details»
Athenex Partners with Leading Contract Manufacturer ... - BioSpace
May 31, 2022 Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of …See details»
Athenex - Contacts, Employees, Board Members, Advisors & Alumni
Athenex is a biopharmaceutical company that develops and discovers novel therapies for treating cancer and related conditions.See details»
Drugmaker Athenex voluntarily files for U.S. Chapter 11 proceedings
May 14, 2023 Athenex reached an agreement with its lenders to move forward with an expedited sale process of its assets, the company said in a statement. The Buffalo, New York-based …See details»
Athenex Announces Exclusive License Agreement with National
Nov 9, 2021 Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and …See details»
Athenex and the Center for Cell and Gene Therapy Announce …
BUFFALO, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), the leading developer of NKT cell therapy and the Center for Cell and Gene Therapy at Baylor College of …See details»
Athenex and the Center for Cell and Gene Therapy Announce
Oct 18, 2021 Texas Children’s Hospital, a not-for-profit health care organization, is committed to creating a healthier future for children and women throughout the global community by leading …See details»
Athenex Receives FDA Complete Response Letter for Oral
Mar 1, 2021 --Athenex, Inc.,, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related …See details»
Athenex Provides Fourth Quarter and Full Year 2022 Financial …
Mar 20, 2023 Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss …See details»